Tue.Mar 05, 2024

article thumbnail

Government, Industry Leaders Address the Growing Issue of PBM Practices

Drug Topics

Health care professionals, industry leaders, and politicians gathered for a virtual roundtable to discuss the state of the PBM industry.

257
257
article thumbnail

FDA Grants Fast Track Designation For EP0031/A400 to Treat RET-Altered NSCLC

Pharmacy Times

The next-generation SRI was previously granted an Orphan Drug Designation in November 2023 and its safety and efficacy are currently being evaluated in clinical trials.

FDA 145
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA Approves Eye Drops to Treat Inflammation, Pain After Ocular Surgery

Drug Topics

Clobetasol propionate ophthalmic suspension 0.05% is the first ophthalmic clobetasol propionate product approved by the FDA and is the first new ophthalmic steroid on the market in over 15 years.

FDA 138
article thumbnail

FDA Approves 2 Denosumab Biosimilars for All Indications of Reference Products

Pharmacy Times

Denosumab-bbdz (Wyost; Sandoz) and denosumab-bbdz (Jubbonti; Sandoz) are approved as interchangeable for all indications of Xgeva (denosumab; Amgen) and Prolia (denosumab; Amgen).

FDA 139
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

How the U.S. is sabotaging its best tools to prevent deaths in the opioid epidemic

STAT

The opioid overdose epidemic has burned through the U.S. for nearly 30 years. Yet for all that time, the country has had tools that are highly effective at preventing overdose deaths: methadone and buprenorphine. These medicines are cheap and easy to distribute. People who take them use illicit drugs at far lower rates, and are at far lower risk of overdose or death.

145
145
article thumbnail

Understanding the Persistence of Pneumococcal Disease in Vaccinated Adults

Pharmacy Times

Investigators also found that those with community-acquired, radiology-confirmed pneumonia with lower respiratory tract infections had worse outcomes.

Vaccines 145

More Trending

article thumbnail

Breaking: FDA Clears Dexcom Stelo, First OTC Continuous Glucose Monitor

Drug Topics

Dexcom's Stelo will be available in summer 2024.

FDA 201
article thumbnail

Watch: Why fentanyl withdrawal is agony and how medication can prevent it

STAT

Over 2 million Americans have opioid use disorder, according to some estimates. Illicit opioids such as heroin and fentanyl were responsible for over 80,000 U.S. overdose deaths in 2023. Despite the known risks, these drugs are notoriously hard to stop using — due in large part to how debilitating withdrawal can be.

145
145
article thumbnail

FDA Clears First OTC Continuous Glucose Monitoring, Dexcom Stelo Glucose Biosensor System

Pharmacy Times

The continuous glucose monitoring system will be available for purchase online and without a prescription starting in summer 2024.

FDA 149
article thumbnail

STAT+: Harvard longevity scientist sparks furor with claim about reversing aging in dogs

STAT

Renowned Harvard University geneticist and longevity researcher David Sinclair recently made an astonishing assertion: Scientists had developed the first pill — well, a soft, beef-flavored chew — “proven to reverse aging” in dogs. Which miracle molecules delivered this supposed scientific breakthrough, he didn’t say.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Insurers report significant reduction in claims data following Change Healthcare hack

Fierce Healthcare

Humana and Elevance Health said they are seeing a 15% to 20% reduction in data from providers after the Change Healthcare hack, company execs said during an industry conference March 5. | Both Humana and Elevance Health said the Change Healthcare cyberattack is affecting its claims data from providers. The plans are increasingly relying on Availity, a competing clearinghouse to handle claims processing.

Insurance 132
article thumbnail

STAT+: FDA clears first over-the-counter continuous glucose monitor

STAT

For the first time, anyone in the United States will soon be able to buy a continuous glucose monitor without a prescription. The Food and Drug Administration authorized Dexcom on Tuesday to start selling a new product, called the Stelo, to adults who do not use insulin. The product is scheduled to hit the market this summer.    The Stelo product is explicitly designed for people with type 2 diabetes who are not reliant on insulin, or people without diabetes who are curious about

FDA 143
article thumbnail

CORe Initiative Looks to Transform Cancer Research Through Increased Diversity and Data Sharing

Pharmacy Times

The CORe initiative is aimed at promoting inclusivity, reducing startup time for clinical trials, and facilitating data sharing to address recruitment and retention challenges in cancer research at community oncology sites.

121
121
article thumbnail

It’s time to stop treating menopause like a disease, researchers argue in series of Lancet articles

STAT

One in eight people is postmenopausal, and about 50 million women enter menopause every year. A new essay published on Tuesday in The Lancet argues that it’s time to stop treating them like patients suffering from a disorder. The article calls for a reframing of menopause and a management approach that is not simply focused on medical interventions that relieve symptoms.

142
142
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

FLOW Trial Results Demonstrate Positive Kidney Outcomes With Semaglutide

Pharmacy Times

In the study, investigators found superior kidney outcomes with injectable semaglutide (Ozempic) for individuals with type 2 diabetes and chronic kidney disease.

123
123
article thumbnail

Q&A: Microsoft research head explains how generative AI could help doctors be more human

STAT

Generative AI is having a moment. Peter Lee, who oversees Microsoft’s approach to health care and co-authored the 2023 book “ The AI Revolution in Medicine: GPT-4 and Beyond, ” calls it “the most transformative tool ever developed in all aspects of health care and medicine.” Microsoft has been collaborating with the organization OpenAI for several years, so when OpenAI released ChatGPT in November 2022, Lee quickly realized there was a need to educate the medic

130
130
article thumbnail

Bayer CEO launches ‘full-scale effort’ to rejuvenate pharma pipeline, tables split-up but warns not never

Fierce Pharma

Bill Anderson, nine months into Bayer’s CEO role, has laid out his priorities for the troubled German conglomerate in the next few years—and it doesn’t involve an immediate business split-up as man | Bill Anderson, nine months into Bayer’s CEO role, has laid out his priorities for the troubled German conglomerate in the next few years—and it doesn’t involve an immediate business split-up as many investors had hoped for.

120
120
article thumbnail

STAT+: WTO proposal for Covid diagnostics and therapeutics waiver is abandoned

STAT

After 18 months of debate, the World Trade Organization failed to adopt a controversial proposal to waive intellectual property protection for Covid-19 diagnostics and treatments, ending a furious attempt by civil society groups to bolster global access to needed medical products. The failure was not a surprise. Since the proposal was introduced, the pharmaceutical industry — and several key countries where large drugmakers are headquartered, including the U.K. and Switzerland — su

Vaccines 130
article thumbnail

FDA Grants Orphan Drug Designation for CBL-514 to Treat Adult Patients With Dercum Disease

Pharmacy Times

This designation makes CBL-514 the first drug to receive both Orphan Drug Designation and Fast Track Designation for the treatment of Dercum disease.

FDA 123
article thumbnail

FDA advisory panel recommends a streamlined flu vaccine for next fall

STAT

When Americans line up for flu vaccines next fall, they will almost certainly be getting vaccines that no longer contain protection against a family of flu viruses that appears to be extinct. Experts who advise the Food and Drug Administration on vaccine-related issues voted unanimously on Tuesday to recommend that the FDA approve trivalent flu vaccines for the 2024-2025 season, instead of the quadrivalent, or four-in-one, shots that have been the industry standard for the past decade or so.

Vaccines 127
article thumbnail

Health Care Transparency Comes in Many Forms, But Is Much Needed in Patient Care

Pharmacy Times

Laws can help eliminate common barriers to transparency but are not the only way to achieve health care transparency.

article thumbnail

Opinion: How ideas from ancient Greece like ‘a bun in the oven’ continue to affect reproductive health policy

STAT

On Jan. 22, 1973, the U.S. Supreme Court handed down its decision in Roe v. Wade, declaring a Texas law prohibiting abortion, and similar laws in other states, to be unconstitutional. Not quite 50 years later, on June 24, 2022, the Supreme Court overturned the Roe decision. In Dobbs v. Jackson Women’s Health Organization, the court declared: “The Constitution does not confer a right to abortion.

127
127
article thumbnail

Novo Nordisk's success with Ozempic in diabetes and kidney disease patients isn't enough for investors

Fierce Pharma

A trial of Novo Nordisk's Ozempic on diabetes and kidney disease patients found that it reduced the risk of disease progression and death by 24%.

128
128
article thumbnail

Air quality improvements belie rising racial and ethnic disparities in pollutant-related deaths, study finds

STAT

The U.S. is making progress in reducing the public health consequences of air pollutants and fine particulate matter. But these improvements have not benefited everyone equally, according to a new study published on Wednesday in the journal Environmental Health Perspective. Researchers found an overall drop from 2010 and 2019 in death and disease linked to nitrogen dioxide (NO2), an air pollutant produced from fossil fuel burning, and fine particulate matter (PM2.5) pollution.

125
125
article thumbnail

Environmental Toxin BPA Affects Gut Microbial Communities in Children

Pharmacy Times

Children with normal weight had different community relationships compared to children with overweight or obesity.

139
139
article thumbnail

STAT+: Large insurers say up to one-quarter of claims run through Change Healthcare

STAT

Some of the country’s biggest health insurers said Tuesday that up to one-quarter of their claims are run through Change Healthcare, UnitedHealth Group’s technology company that sustained a massive cyberattack two weeks ago. Speaking at investor conferences, executives from Humana, Elevance Health, and CVS Health, which owns Aetna, said the biggest impact they’re seeing is fewer bills coming in from providers.

Insurance 121
article thumbnail

Surprise Enhertu rejection follows NICE process change

pharmaphorum

NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”.

115
115
article thumbnail

STAT+: Q&A: Nora Volkow on how to get ‘at least 50% less people dying’ from opioid overdose

STAT

In 2003, the year Nora Volkow was appointed director of the National Institute on Drug Abuse, roughly 4,000 Americans died of opioid overdose. In the two decades since, the overdose crisis has morphed into a full-fledged public health emergency, with 80,000 Americans dying from opioid overdoses each year. But in that stretch, relatively little has changed about the way the U.S. treats opioid addiction.

118
118
article thumbnail

Vanda's jet-lag approval hopes for Hetlioz quashed with FDA hearing rejection

Fierce Pharma

Vanda has been waiting years for an FDA hearing to contest the agency’s 2019 rejection of its sleep drug Hetlioz in jet lag disorder. | Vanda has been waiting years for an FDA hearing to contest the agency’s 2019 rejection of its sleep drug Hetlioz in jet lag disorder. Now, following a lawsuit and a protracted back-and-forth with the U.S. regulator, the FDA has crushed Vanda’s bid.

FDA 115
article thumbnail

Walgreens plans strategic review of business, including the role of its retail stores, healthcare assets, CEO says

Fierce Healthcare

Walgreens is gearing up for a strategic review of its business, including the role of its retail pharmacy stores and its healthcare assets, as company leadership and the board plot the future direc | The drugstore retail giant making moves to improve its financial performance after a massive growth spurt in which it expanded its healthcare business segment.

115
115
article thumbnail

Coherus launches Udenyca wearable injector device

Drug Store News

The on-body device delivers Udenyca, a biosimilar pegfilgrastim administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.

article thumbnail

Memorial Hermann taps Charlie Health to fill gaps in critical mental health services

Fierce Healthcare

Houston-based Memorial Hermann Health System is partnering with Charlie Health to expand access to outpatient mental health treatment for teens and young adults. | "Partnering with Charlie Health excited us because they offer newer technology, evidence-based care in a virtual setting and data that support their treatment program," Dr. Victoria Regan, vice president, women's and children's service line at Memorial Hermann said.

114
114
article thumbnail

Where’s Lilly’s Alzheimer’s approval?

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Hello, everyone. Damian here. I’d like to heartily recommend you  check out Part 1 of The War on Recovery , a yearlong STAT investigation into how the U.S. denies lifesaving medications to people with opioid addiction.

112
112
article thumbnail

NICE backs frontline use of Jemperli in endometrial cancer

pharmaphorum

GSK’s PD-1 inhibitor Jemperli has been cleared for use by the NHS as a first-line treatment for a specific type of endometrial cancer, making it an option for around 580 women across England, Wales and Northern Ireland.

110
110